Hepatology Research Unit, Department of Internal Medicine and Pediatrics, Liver Research Center Ghent, Ghent, Belgium; Gut-Liver Immunopharmacology Unit, Department of Basic and Applied Medical Sciences, Liver Research Center Ghent, Ghent, Belgium.
Zeepreventorium, De Haan, Belgium.
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2317-2326.e4. doi: 10.1016/j.cgh.2021.11.039. Epub 2021 Dec 4.
BACKGROUND & AIMS: Childhood obesity, with associated comorbidities such as nonalcoholic fatty liver disease (NAFLD), is an increasing global health problem. Although lifestyle management is the mainstay of treatment, its efficacy on liver fibrosis has not yet been established.
Children and adolescents admitted for severe obesity at a tertiary center (Zeepreventorium, De Haan, Belgium) were enrolled in this prospective study. Intensive lifestyle therapy encompassed caloric restriction, physical activity, education on a healthy lifestyle, and psychosocial support. At baseline, 6 months, and 12 months, liver ultrasound and transient elastography with controlled attenuation parameter were performed to assess liver steatosis and fibrosis.
A total of 204 patients (median age, 14.0 y; body mass index Z-score, +2.8) were evaluated at admission. NAFLD on ultrasound was present in 71.1%, whereas 68.6% had controlled attenuation parameter values of 248 dB/m or greater. A total of 32.8% of patients had at least F2 fibrosis, including 10.3% with transient elastography of 9 kPa or greater. After 6 months, the median body weight loss was 16.0% in the 167 patients evaluated. Fibrosis improved in 75.0% (P < .001). Baseline severity of liver fibrosis and steatosis were predictors of fibrosis resolution. Seventy-nine patients had reached the 1-year time point. The improvements were sustained because fibrosis regressed at least 1 stage in all patients with baseline fibrosis. Fasting serum alanine aminotransferase and homeostasis model assessment of insulin resistance decreased significantly over the 1-year period (P < .001).
NAFLD and associated fibrosis are highly prevalent in children and adolescents with severe obesity. An intensive multidisciplinary lifestyle management program that causes significant weight loss not only improves liver steatosis, but also fibrosis.
儿童肥胖症与非酒精性脂肪性肝病(NAFLD)等相关合并症是一个日益严重的全球性健康问题。虽然生活方式管理是治疗的主要方法,但它对肝纤维化的疗效尚未得到证实。
本前瞻性研究纳入了在比利时德汉的一家三级中心(Zeepreventorium)因严重肥胖而入院的儿童和青少年患者。强化生活方式治疗包括热量限制、体力活动、健康生活方式教育和心理社会支持。在基线、6 个月和 12 个月时,进行肝脏超声和瞬时弹性成像检查,以评估肝脂肪变性和纤维化。
共 204 名患者(中位年龄 14.0 岁;体重指数 Z 评分+2.8)在入院时接受了评估。超声检查显示 71.1%的患者存在 NAFLD,而 68.6%的患者控制衰减参数值≥248dB/m。共有 32.8%的患者至少存在 F2 纤维化,其中 10.3%的患者瞬时弹性成像值≥9kPa。在 6 个月时,167 名接受评估的患者中位体重减轻了 16.0%。纤维化改善了 75.0%(P <.001)。基线肝纤维化和脂肪变性的严重程度是纤维化缓解的预测因素。79 名患者达到了 1 年时间点。由于所有基线纤维化患者的纤维化均至少降低了 1 个阶段,因此改善得以维持。在 1 年期间,空腹血清丙氨酸氨基转移酶和稳态模型评估的胰岛素抵抗显著降低(P <.001)。
在患有严重肥胖症的儿童和青少年中,NAFLD 和相关纤维化非常普遍。一个多学科的强化生活方式管理方案,在显著减轻体重的同时,不仅可以改善肝脂肪变性,还可以改善纤维化。